Mountain View, United States
Turn Biotechnologies, founded in 2018 and headquartered in the United States, is pioneering longevity solutions aimed at combating diseases of aging. With the slogan "Turn Bio is developing longevity solutions to combat diseases of aging by restoring youthful performance to adult cells," the company addresses multiple aging-related conditions through an innovative reprogramming therapy.
Their proprietary approach involves a transiently-administered rejuvenation cocktail, which effectively reverses eight out of the nine "Hallmarks of Aging" as defined in a seminal 2013 paper in Cell. This strategy positions the company as a frontrunner in the field of age-related therapeutic interventions.
While the exact investment amounts remain undisclosed, Turn Biotechnologies has garnered support from recognizable investors such as Khosla Ventures, Astellas Venture Management, Formic Ventures, ThreeD Capital, LongeVC, Methuselah Funds, along with strategic partners like Daewoong Pharmaceutical and Shanda Group, as demonstrated by their last financing round on 01 April 2022.
